STOK
Stoke Therapeutics·NASDAQ
--
--(--)
--
--(--)
STOK fundamentals
Stoke Therapeutics (STOK) released its earnings on Nov 4, 2025: revenue was 10.63M (YoY +117.25%), beat estimates; EPS was -0.65 (YoY -38.30%), missed estimates.
Revenue / YoY
10.63M
+117.25%
EPS / YoY
-0.65
-38.30%
Report date
Nov 4, 2025
STOK Earnings Call Summary for Q3,2025
- Phase 3 Momentum: Over 200 patients pre-screened for Emperor, with 20 randomized, targeting H2 2026 enrollment completion.
- FDA Engagement: Multidisciplinary meeting highlights potential expedited pathways, leveraging 4-year data showing 80% seizure reduction and VABS-III improvements.
- Financial Strength: $328.6M cash runway, 126% YoY revenue growth, and $48.7M ATM raise support long-term growth.
- Pipeline Innovation: ADOA shows functional vision recovery in preclinical models; SYNGAP1 advancing with CNS platform validation.
EPS
Actual | -0.34 | -0.39 | -0.41 | -0.42 | -0.46 | -0.6 | -0.61 | -0.66 | -0.66 | -0.63 | -0.66 | -0.65 | -0.53 | -0.69 | -0.55 | -0.6 | -0.57 | -0.46 | -0.47 | -0.18 | 1.9 | -0.4 | -0.65 | |||
Forecast | -0.3622 | -0.3533 | -0.4089 | -0.4117 | -0.4217 | -0.461 | -0.5704 | -0.6234 | 0.3619 | -0.6876 | -0.6843 | -0.713 | -0.7009 | -0.6347 | -0.6325 | -0.6086 | -0.6099 | -0.5481 | -0.52 | -0.5282 | 0.109 | -0.512 | -0.5682 | |||
Surprise | 0.00% | 0.00% | 0.00% | +6.13% | -10.39% | -0.27% | -2.02% | -9.08% | -30.15% | -6.94% | -5.87% | -282.37% | +8.38% | +3.55% | +8.84% | +24.38% | -8.71% | +13.04% | +1.41% | +6.54% | +16.07% | +9.62% | +65.92% | +1643.12% | +21.88% | -14.40% |
Revenue
Actual | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.00M | 3.23M | 2.90M | 3.27M | 5.15M | -2.48M | 3.31M | 2.80M | 4.22M | 4.83M | 4.89M | 22.61M | 158.57M | 13.82M | 10.63M |
Forecast | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50.00M | 2.64M | 2.72M | 2.86M | 3.00M | 3.44M | 3.64M | 3.66M | 3.26M | 3.70M | 3.83M | 4.28M | 29.39M | 8.91M | 6.16M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.00% | +22.36% | +6.71% | +14.19% | +71.73% | -172.03% | -9.19% | -23.54% | +29.32% | +30.47% | +27.83% | +428.36% | +439.58% | +55.05% | +72.60% |
Earnings Call
You can ask Aime
What is Stoke Therapeutics's gross profit margin?What does Stoke Therapeutics do and what are its main business segments?What guidance did Stoke Therapeutics's management provide for the next earnings period?What is the market's earnings forecast for Stoke Therapeutics next quarter?What is Stoke Therapeutics's latest dividend and current dividend yield?What were the key takeaways from Stoke Therapeutics’s earnings call?What factors drove the changes in Stoke Therapeutics's revenue and profit?Did Stoke Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
